Related Experiment Videos
Drug therapy for hyperlipidemia. When reducing cardiovascular risk is a priority
1Lipid Center, Humana Heart Institute International, Louisville, KY 40217.
Insights
Physicians can stay updated on lipid-lowering agents with this review. It covers major antihyperlipidemics, patient selection, and cost-effectiveness for managing high cholesterol.
Area of Science:
- Cardiology
- Pharmacology
Background:
- The field of lipid-lowering agents is rapidly evolving.
- Keeping abreast of the latest research is challenging for busy clinicians.
Purpose of the Study:
- To provide an update on major antihyperlipidemic medications.
- To guide patient selection for lipid-lowering therapy.
- To discuss the cost-effectiveness of various treatment options.
Main Methods:
- Review of current literature on antihyperlipidemic agents.
- Analysis of patient profiles for optimal therapy selection.
- Comparative assessment of cost-effectiveness.
Main Results:
- Overview of currently available major lipid-lowering drugs.
- Guidance on identifying appropriate candidates for therapy.
- Evaluation of economic factors influencing treatment choices.
Conclusions:
- This review offers a practical update for clinicians managing dyslipidemia.
- Informed patient selection and cost-effectiveness analysis are crucial for optimal antihyperlipidemic therapy.
Abstract:
If you are confused about the plethora of lipid-lowering agents now available and have not been able to read all the latest studies, you are not alone. It is almost impossible for busy physicians to keep up with this rapidly growing area of research. Drs Bays and Dujovne provide an update of the major antihyperlipidemics, along with a discussion of how to select patients for this therapy and the relative cost-effectiveness of the different types of therapy.